Type Public | Industry Biotechnology Founded 1980 | |
Traded as OTC Pink No Information: UGNEQ Key people Ashleigh Palmer, President and CEO
Gregory T. Mayes, Esq., Vice President, Corporate Development and General Counsel
Nozer Mehta, Ph.D., Vice President, Biological Research and Development
Paul Shields, Ph.D., Vice President, Technology Transfer and Contract Manufacturing Services
William Steinhauer, CPA Vice President, Finance
Roxanne Tavakkol, Vice President, Global Regulatory Affairs
Jenene Thomas,
Vice President, Investor Relations and Business Administration Stock price UGNEQ (OTCMKTS) US$ 0.00 0.00 (-25.00%)30 Mar, 4:00 PM GMT-4 - Disclaimer Headquarters Boonton, New Jersey, United States | ||
Unigene Laboratories (OTC:UGNE) was a biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey.
The company's primary focus is on the development of calcitonin and related peptides for the treatment of osteoporosis. The company has licensed worldwide rights to its oral parathyroid hormone ("PTH") to GlaxoSmithKline.
Unigene filed for Chapter 7 bankruptcy on July 2, 2013 in the United States Bankruptcy Court of the District of New Jersey. The Chapter 7 case is being administered under case No. 13-24696.
References
Unigene Laboratories Wikipedia(Text) CC BY-SA